Oragenics (NYSEAMERICAN:OGEN) Trading Down 1.5% – What’s Next?

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s share price was down 1.5% on Thursday . The stock traded as low as $0.5820 and last traded at $0.6010. Approximately 28,953 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 61,574 shares. The stock had previously closed at $0.61.

Oragenics Stock Performance

The firm has a market cap of $2.68 million, a P/E ratio of -0.03 and a beta of 1.27. The company has a 50 day moving average of $0.60 and a 200 day moving average of $0.76.

Oragenics (NYSEAMERICAN:OGEN) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.51) EPS for the quarter.

Institutional Trading of Oragenics

Large investors have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Oragenics during the fourth quarter valued at about $26,000. Bank of America Corp DE lifted its position in shares of Oragenics by 7,374.0% in the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after acquiring an additional 15,338 shares during the period. Sabby Management LLC acquired a new stake in Oragenics during the third quarter worth $77,000. Finally, DRW Securities LLC boosted its stake in Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after buying an additional 50,900 shares in the last quarter. Institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.